Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 EBIT

The latest EBIT for BLACR is $-21M as of June 2026. That compares with $-11M in the prior-year period — down 85.0% year over year. That is above the sector sector average of $-26M. Investors often review this figure alongside Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLACR's EBIT moved from $-11M to $-21M — a 85.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's operating scale or balance-sheet position.

Against its sector companies, BLACR currently prints $-21M for EBIT, while the sector average sits near $-26M. That is roughly 20.0% above the sector mean. Large gaps often invite a closer look at Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's growth, margins, and balance sheet.

A EBIT figure of $-21M for BLACR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-26M. Explore the charts below for those layers of context.

After noting BLACR's EBIT ($-21M), review year-over-year change from $-11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.